Quantinno Capital Management LP Buys 66,128 Shares of Genmab A/S (NASDAQ:GMAB)

Quantinno Capital Management LP grew its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 273.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 90,335 shares of the company's stock after purchasing an additional 66,128 shares during the period. Quantinno Capital Management LP's holdings in Genmab A/S were worth $1,885,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its holdings in Genmab A/S by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 8,891 shares of the company's stock worth $186,000 after purchasing an additional 827 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after buying an additional 939 shares during the period. Lindbrook Capital LLC increased its stake in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after acquiring an additional 950 shares in the last quarter. Grandfield & Dodd LLC increased its stake in shares of Genmab A/S by 4.2% in the 4th quarter. Grandfield & Dodd LLC now owns 33,733 shares of the company's stock worth $704,000 after acquiring an additional 1,370 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in Genmab A/S by 33.4% during the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after acquiring an additional 1,442 shares during the period. Hedge funds and other institutional investors own 7.07% of the company's stock.

Genmab A/S Trading Up 1.7%

GMAB stock traded up $0.35 during midday trading on Tuesday, hitting $21.16. The company's stock had a trading volume of 169,100 shares, compared to its average volume of 1,128,203. The firm's 50-day moving average is $19.78 and its 200-day moving average is $20.65. Genmab A/S has a 12 month low of $17.24 and a 12 month high of $28.96. The company has a market cap of $13.57 billion, a PE ratio of 12.14, a P/E/G ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The firm had revenue of $715.00 million during the quarter, compared to analysts' expectations of $5.17 billion. Analysts expect that Genmab A/S will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. Leerink Partners upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a report on Thursday, February 13th. BNP Paribas raised Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. HC Wainwright reissued a "buy" rating and issued a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research note on Wednesday, April 9th. Finally, Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a report on Tuesday, April 1st. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $39.17.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.